Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625...
Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C Yahoo/Globe NewsWire
View Article5 Biotech Stocks That Could Soar On New Hepatitis C Drugs
5 Biotech Stocks That Could Soar On New Hepatitis C Drugs Seeking Alpha
View ArticleAchillion's hepatitis C drug gets FDA fast track
Achillion's hepatitis C drug gets FDA fast track Reuters
View ArticleAchillion Announces Positive Proof-of-Concept Data With ACH-3102
Achillion Announces Positive Proof-of-Concept Data With ACH-3102 Yahoo
View Article5 Drug Hopefuls That Are Going to Change Your Life: Part 2
5 Drug Hopefuls That Are Going to Change Your Life: Part 2 Motley Fool
View ArticleAchillion Says Hepatitis C Drug Subdues Virus in 63% of Patients
Achillion Says Hepatitis C Drug Subdues Virus in 63% of Patients Bloomberg
View ArticleBiotech Stock Mailbag: 2013 Clinical Trials Calendar
Biotech Stock Mailbag: 2013 Clinical Trials Calendar TheStreet.com
View ArticleAchillion May Be The Most Underrated Biotech Left
Achillion May Be The Most Underrated Biotech Left Seeking Alpha
View Article
More Pages to Explore .....
